HTG/ Sanofi US Annouce Biomarker Collaboration
HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers
Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine
TUCSON, Ariz. (March 30, 2012) – HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics' qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.
"We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies," said TJ Johnson, CEO of HTG Molecular Diagnostics.